Prognosis in Triple Negative Breast Cancer Using Immunohistochemical Markers
Author Information
Author(s): Marc Tischkowitz, Jean-Sébastien Brunet, Louis R Bégin, David G Huntsman, Maggie Cheang, Lars A Akslen, Torsten O Nielsen, William D Foulkes
Primary Institution: McGill University
Hypothesis
Different combinations of immunohistochemical patterns affect prognosis in triple negative breast cancer.
Conclusion
CK5/6 and/or EGFR expressing tumor types have a persistently poorer prognosis over the longer term.
Supporting Evidence
- The study found a significant difference in survival rates between triple negative and non-triple negative groups at 3 years.
- Long-term survivors in the triple negative group may have comparable survival to non-triple negative cases.
- CK5/6 and/or EGFR expressing tumors showed a greater reduction in survival over time.
Takeaway
This study shows that certain markers can help predict how well patients with a specific type of breast cancer will do over time.
Methodology
The study analyzed data from two hospitals, comparing survival rates based on different immunohistochemical patterns.
Potential Biases
Potential biases due to the retrospective nature of the study and selection of cases.
Limitations
The study is retrospective and may not account for all variables affecting prognosis.
Participant Demographics
The study included women diagnosed with invasive breast cancer, with a focus on Ashkenazi Jewish women in one cohort.
Statistical Information
P-Value
p < .0001
Confidence Interval
95% C.I. 6.05–51.5
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website